Martin Zapata Laguado, Clinical Oncologist at Instituto Nacional de Cancerología in Bogotá, shared on X:
“ESMO26 | LITESPARK-011 in advanced RCC Belzutifan + lenvatinib vs cabozantinib after IO :
No significant OS benefit (HR 0.85; p=0.0469; prespecified one-sided boundary 0.0223), the primary OS endpoint was not met.”
Learn more: LITESPARK-011 at ESMO 2026: Association Between HRQoL and Clinical Outcomes in Advanced RCC
